Gilead Sciences (NASDAQ: GILD) and Vascular Biogenics (NASDAQ:VBLT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Gilead Sciences and Vascular Biogenics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Gilead Sciences $28.47 billion 3.77 $17.97 billion $9.21 8.93
Vascular Biogenics N/A N/A -$18.32 million ($0.67) -7.84

Gilead Sciences has higher revenue and earnings than Vascular Biogenics. Vascular Biogenics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Gilead Sciences and Vascular Biogenics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences 0 9 17 0 2.65
Vascular Biogenics 0 0 4 0 3.00

Gilead Sciences currently has a consensus price target of $84.05, indicating a potential upside of 2.16%. Vascular Biogenics has a consensus price target of $14.75, indicating a potential upside of 180.95%. Given Vascular Biogenics’ stronger consensus rating and higher possible upside, analysts plainly believe Vascular Biogenics is more favorable than Gilead Sciences.

Insider and Institutional Ownership

74.1% of Gilead Sciences shares are owned by institutional investors. Comparatively, 11.3% of Vascular Biogenics shares are owned by institutional investors. 1.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


This table compares Gilead Sciences and Vascular Biogenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gilead Sciences 42.90% 66.07% 23.03%
Vascular Biogenics N/A -44.15% -39.46%

Risk & Volatility

Gilead Sciences has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Vascular Biogenics has a beta of -3.15, meaning that its share price is 415% less volatile than the S&P 500.


Gilead Sciences pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. Vascular Biogenics does not pay a dividend. Gilead Sciences pays out 22.6% of its earnings in the form of a dividend.


Gilead Sciences beats Vascular Biogenics on 11 of the 14 factors compared between the two stocks.

Gilead Sciences Company Profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with's FREE daily email newsletter.